Literature DB >> 7524322

Elevated second-trimester human chorionic gonadotropin levels in association with poor pregnancy outcome.

K D Wenstrom1, J Owen, L R Boots, M B DuBard.   

Abstract

OBJECTIVE: Our purpose was to determine whether abnormal pregnancy outcome is associated with elevated maternal serum human chorionic gonadotropin levels. STUDY
DESIGN: Maternal serum alpha-fetoprotein and human chorionic gonadotropin levels were measured in stored second-trimester serum obtained before scheduled genetic amniocentesis from 126 women with poor pregnancy outcomes, excluding aneuploidy and structural abnormalities (complications group), and 126 matched women with normal outcomes (control group).
RESULTS: More women with complications had elevated human chorionic gonadotropin levels (> or = 2.0 multiples of the median) (14%) than did control women (3%) (p = 0.01). Both elevated human chorionic gonadotropin and maternal serum alpha-fetoprotein levels were significantly associated with preterm delivery and fetal death. Elevated maternal serum alpha-fetoprotein was significantly associated with early postamniocentesis complications and fetal growth restriction, whereas elevated human chorionic gonadotropin was associated with preeclampsia.
CONCLUSION: Elevated human chorionic gonadotropin, similar to unexplained elevated maternal serum alpha-fetoprotein, is significantly associated with abnormal pregnancy outcomes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524322     DOI: 10.1016/0002-9378(94)90030-2

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

Review 1.  Nausea and vomiting of pregnancy.

Authors:  Noel M Lee; Sumona Saha
Journal:  Gastroenterol Clin North Am       Date:  2011-06       Impact factor: 3.806

2.  The role of unexplained high serum alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG) levels in the second trimester to determine poor obstetric outcomes.

Authors:  Hümeyra Öztürk; Salim Erkaya; Sibel Altınbaş; Burak Karadağ; Nazan Vanlı Tonyalı; Demet Özkan
Journal:  Turk J Obstet Gynecol       Date:  2014-09-15

3.  Update and Review: Maternal Serum Screening.

Authors:  K E Ormond
Journal:  J Genet Couns       Date:  1997-12       Impact factor: 2.537

4.  Second trimester serum alpha-fetoprotein level is a significant positive predictor for intrauterine growth restriction in pregnant women with hyperemesis gravidarum.

Authors:  Enis Ozkaya; Evrim Cakır; Mehmet Cınar; Metin Altay; Orhan Gelişen; Fadıl Kara
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-12-01

5.  Early onset preeclampsia in a model for human placental trophoblast.

Authors:  Megan A Sheridan; Ying Yang; Ashish Jain; Alex S Lyons; Penghua Yang; Sambasiva R Brahmasani; Aihua Dai; Yuchen Tian; Mark R Ellersieck; Geetu Tuteja; Danny J Schust; Laura C Schulz; Toshihiko Ezashi; R Michael Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-20       Impact factor: 11.205

Review 6.  Emerging Progress in Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum: Challenges and Opportunities.

Authors:  Chuan Liu; Guo Zhao; Danni Qiao; Lintao Wang; Yeling He; Mingge Zhao; Yuanyuan Fan; Enshe Jiang
Journal:  Front Med (Lausanne)       Date:  2022-01-10

7.  Record linkage to obtain birth outcomes for the evaluation of screening biomarkers in pregnancy: a feasibility study.

Authors:  Samantha J Lain; Charles S Algert; Vitomir Tasevski; Jonathan M Morris; Christine L Roberts
Journal:  BMC Med Res Methodol       Date:  2009-07-09       Impact factor: 4.615

Review 8.  The Prenatal Hormone Milieu in Autism Spectrum Disorder.

Authors:  Whitney Worsham; Susan Dalton; Deborah A Bilder
Journal:  Front Psychiatry       Date:  2021-07-01       Impact factor: 4.157

9.  The role of maternal serumbeta-HCG and PAPP-A levels at gestational weeks 10 to 14 in the prediction of pre-eclampsia.

Authors:  Ozkan Ozdamar; Ismet Gun; Ugur Keskin; Necmettin Kocak; Ercument Mungen
Journal:  Pak J Med Sci       Date:  2014-05       Impact factor: 1.088

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.